PRiiMO

Company Overview

Snapshot

Founded in March 2019 by Amit Gilboa, Prof. Philip Stricker, and Arnon Yaar, PRiiMO operated with 1–10 employees. The company secured $2M in total capital across one funding round from two investors. In June 2023, PRiiMO ceased operations.

Business overview

PRiiMO developed a digital platform that leverages an AI-based precision medicine engine to personalize cancer treatment plans for patients and physicians. The platform integrates diverse data sources, including medical records, genomics, imaging, and patient behavior, to generate data analytics and actionable insights. Initially focusing on prostate cancer, PRiiMO aimed to serve urologists and their patients while building a comprehensive multi-source data asset for this disease domain. The company operated in the Health Tech & Life Sciences sector, specifically within Digital Healthcare and Medical Decision Support, targeting patients and healthcare providers in the United States and Australia.

Company Intelligence Q&A

What is PRiiMO's primary focus?

PRiiMO's primary focus is on developing an AI-based precision medicine engine to personalize cancer treatment plans for patients and their physicians, initially concentrating on prostate cancer.

When was PRiiMO founded and by whom?

PRiiMO was founded in March 2019 by Amit Gilboa, Prof. Philip Stricker, and Arnon Yaar.

What is the status of PRiiMO?

PRiiMO ceased operations in June 2023.

What was PRiiMO's total disclosed funding?

PRiiMO raised $2M in total disclosed funding across one round in May 2019, with investments from Qure Ventures and OurCrowd.

Which investors participated in PRiiMO's funding round?

In May 2019, PRiiMO received funding from Qure Ventures and OurCrowd, contributing to a total of $2M raised.